- Research Article
- 10.1016/j.annonc.2025.08.1072
652eTiP A phase Ib/II study of FWD1802, a novel oral estrogen receptor (ER) degrader (SERD), in combination with multiple CDK4/6 inhibitors (CDK4/6i) and mTOR inhibitor in ER+/HER2- advanced or metastatic breast cancer (a/m BC)
- Sep 01, 2025
- Annals of Oncology
- Y Meng + 11 more +11